Loading...
Systemic treatment for metastatic prostate cancer
The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (a...
Saved in:
| Published in: | Asian J Urol |
|---|---|
| Main Author: | |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Second Military Medical University
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488732/ https://ncbi.nlm.nih.gov/pubmed/31061802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2019.02.002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|